Loading…
Loading…
OTCFF does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for OTCFF and 80,000+ other tickers.
See exactly how OTCFF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for OTCFF and 80,000+ other tickers.
Specializing in research and product development, Ocumetics Technology Corp. engineers and manufactures a range of optical lenses. A flagship offering is the Bionic Lens, an innovative, expandable intraocular lens designed to be precisely placed within the eye's natural lens capsule, thereby removing the necessity for traditional corrective eyewear. The company's operations are headquartered in Calgary, Canada.
Calgary, Alberta – TheNewswire - August 24, 2026 - Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the third and final tranche of the private placement previously announced by the Corporation on July 7, July 29, July 30, 2026 and July 31, 2026 (the “ Offering ”). The Corporation has issued an additional 405,000 units (“ Units ”) at a price of $0.40 per unit for aggregate gross proceeds of $162,000. Each Unit consists of one common share in the share capital of the Corporation (“ Common Share ”) and one common share purchase warrant (“ Warrant ”). Each Warrant entitles the holder to purchase one additional Common Share at an exercise price of $0.50 for a period of three years from the date of issuance of the Warrant.
Calgary, Alberta – July 31, 2026 – TheNewswire - Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the second tranche of the private placement previously announced by the Corporation on July 7, July 29 and July 30, 2026 (the “ Offering ”). The Corporation has issued an aggregate of 6,250,000 units (“ Units ”) at a price of $0.40 per unit for aggregate gross proceeds of $2,500,000. Each Unit consists of one common share in the share capital of the Corporation (“ Common Share ”) and one common share purchase warrant (“ Warrant ”). Each Warrant entitles the holder to purchase one additional Common Share at an exercise price of $0.50 for a period of three years from the date of issuance of the Warrant.
Calgary, Alberta – TheNewswire - July 30, 2026. Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that as a result of strong investor demand, it has increased the size of the offering of units at a price of $0.40 per unit (the “ Units ”) previously announced by the Corporation on July 7 and July 29, 2026 (the “ Offering ”) from up to 5,000,000 Units to up to 8,000,000 Units for total gross proceeds of up to $3,200,000. Each unit consists of one common share in the share capital of the Corporation (“ Common Share ”) and one common share purchase warrant (“ Warrant ”). Each Warrant entitles the holder to purchase one additional Common Share at an exercise price of $0.50 for a period of three years from the date of issuance of the Warrant.
Calgary, Alberta – TheNewswire - July 29, 2026. Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the first tranche of the private placement previously announced by the Corporation on July 7, 2026 (the “ Offering ”).
Key Highlights Positive six-month results from the Company's First-in-Human ("FIH") study support advancement to Group Two clinical surgeries